Orexigen Therapeutics, Inc. reviewed that Empatic™, the drug in its investigational stage, has proven to reduce the body weight of obese people, who had undergone year-long treatment without any diet and exercise, by 15%. Also, the company has presented some data on Contrave® that shows a 50% reduction in the prevalence of metabolic syndrome, from baseline, in patients of obesity. Both these products, in their development phase, have high potential of solving obesity problems.